ABVX:EPA
Abivax SA
€114.10
arrow_upward
+3.54%(+3.90) 1 天
8月7日, GMT+2 17:35:17 · EUR
search
所有股票代码
1 天
5 天
1 个月
6 个月
年初至今
1 年
5 年
最大
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 ABVX 生成关键数据洞见…
开盘价
€112.60
最高价
€115.80
最低价
€112.60
市值
九六.九四亿
平均成交量
二四.六五万
成交量
一〇.七二万
52 周最高价
€139.00
52 周最低价
€57.50
每股收益
-€4.49
流通股数
八七二五.三八万
员工人数
八〇
开盘价
€112.60
最高价
€115.80
最低价
€112.60
市值
九六.九四亿
平均成交量
二四.六五万
成交量
一〇.七二万
52 周最高价
€139.00
52 周最低价
€57.50
每股收益
-€4.49
流通股数
八七二五.三八万
员工人数
八〇
资料
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Abivax SA简介